Clinical Trials

By targeting the fundamental underlying mechanisms of neurodegeneration in MS, i.e. neutralizing microglial-mediated damage, as well as restoring oligodendrocyte precursor cells (OPC) remyelination capacity, temelimab may address the critical unmet medical need of blocking disability progression independent of relapses in MS.

Current studies

Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Long-COVID - Fully recruited now

https://clinicaltrials.gov/ct2/show/NCT05497089?term=temelimab&draw=2&rank=1

The GNC-501 study, entitled “Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric Symptoms in Post-COVID-19 or Post-Acute Sequelae of COVID-19 (PASC) Syndrome”, will enroll 200 patients from Swiss and EU study centres suffering from severe neuropsychiatric syndromes following COVID infection. The biomarker-based study will enrol only patients who are also tested positive for the pathogenic protein W-ENV, with the objective to reduce their invalidating conditions.

Current active sites:

SWITZERLAND

Geneva: Hôpital Universitaire de Genève - https://recherche.hug.ch/etudes/temelimab
Service de Premier Recours, Rue Gabrielle-Perret-Gentil 4, 1205 Genève.
Email: etude.longcovid@hcuge.ch

Basel: REHAB Basel Klinik für Neurorehabilitation und Paraplegiologie
Im Burgfelderhof 40, 4055 Basel
https://www.rehab.ch/en/medical-services/special-skills/post-covid-sprechstunde

Bern: INSELSPITAL, Neuroimmunological Study Centre (NIS)
Freiburgstrasse 14, SH2, EG3, 3010 Bern
http://www.neurologie.insel.ch/de/lehre-und-forschung/forschung/research-groups/neuroimmunology/multiple-sclerosis-1/neuroimmunologische-studienambulanz-nis

Chur: Kantonsspital Graubünden - https://www.ksgr.ch/long-covid-sprechstunde.aspx
☎ +41 81 256 72 10

Sion: Hôpital du Valais– Centre hospitalier du Valais Romand -
Hôpital de Sion, Avenue du Grand-Champsec 80, 1950 Sion - Service de pneumologie
www.hopitalvs.ch/covid-long - www.hopitalvs.ch/pneumo  - Marlène Salamin: ☎ +41 27 603 45 57

ITALY

Modena: Azienda Ospedaliero-Universitaria di Modena
Clinica Malattie Infettive - Prof. Giovanni Guaraldi
Via del Pozzo 71, 41124 Modena - ☎ +39-0594222799 - Email clinica.metabolica@gmail.com; nb.protocolli@unimore.it

Rome: U.O.C. Malattie Infettive Tor Vergata, Policlinico Tor Vergata
Contact: Loredana Sarmati, MD, Prf
☎ +39-06.2090.3440 - email: malattie.infettive@ptvonline.postecert.it

Rome: AMBULATORIO POST COVID-19, Palazzina CEMI
Fondazione Policlinico A. Gemelli IRCCS, Largo F. Vito 1 - 00168 Roma
Contact: ☎ +39 06 3015 1 - ambulatoriopostcovid@policlinicogemelli.it

Vipiteno/Sterzing: Ospedale di Vipiteno - Neuroriabilitazione / Krankenhaus Sterzing - Neurorehabilitation
Via S. Margherita, 24 / Margarethen-Straße 24, I-39049 Vipiteno/Sterzing (BZ)
☎ 0472 774 111   -  https://home.asdaa.it/it/ospedali/vipiteno/Neuroriabilitazione.asp

SPAIN

Barcelona: Ace Alzheimer Center, Barcelona
C/ Gran Via de Carles III, 85 bis, 08028 Barcelona, Spain
Contact: Mercé Boada Rovira, MD  - email: assaigsclinics.ace@fundacioace.org
☎ +34 93 444 73 18

Madrid: Blue Healthcare
Av. de Alberto de Alcocer, 5, y 7, 28036 Madrid
☎ +34 91 999 17 70

Madrid: Hospital Universitario Quirónsalud Madrid
Diego de Velázquez, 1. 28223 Pozuelo de Alarcón, Madrid
Contact: Dr Pablo Guisado Vasco - e-mail: pablo.guisado@quironsalud.es
☎ +34 91 452 1900

Valencia: Fundación Hospital General Universitario de Valencia
Avda. Tres Cruces, 2 (acceso B3, 4ª planta)  - 46014 Valencia
☎ +34-963 131 800 - email: fundacion_hgv@gva.es. medicinainterna_hgv@gva.es
https://fihgu.general-valencia.san.gva.es/quienes-somos/localizacion
https://chguv.san.gva.es/servicios-salud/servicios-unidades/medicina-interna

Zaragoza: Hospital Royo Villanova. Avd San Gregorio s/n 50015 Zaragoza
email: cpcovid@salud.aragon.es
☎ +34-976466910 Ext 567066